Studies reveal that tuberculosis risk varies with the use of different anti-TNF-α agents (etanercept, 35 cases per 100,000 patients; infliximab, 144 per 100,000 patients; and adalimumab, 240 per 100,000 patients)[33]. The gene discussed is TNF; the disease is tuberculosis.